药明康德（603259）公告，2025年上半年营业收入207.99亿元，同比增长20.64%。净利润85.61亿元， 同比增长101.92%。公司拟向全体股东每10股派发现金红利人民币3.5元(含税)，共计派发现金红利人民 币10.03亿元(含税)。 ...

公司名稱： 無錫藥明康德新藥開發股份有限公司 呈交日期： 2025年7月28日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | A | | 於香港聯交所上市 | 否 | | | 證券代號 (如上市) | | 說明 | 於上海證券交易所上市 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | 事件 | | 已發行股份（不包括庫存股份）變動 佔有關事件前的現有已發 | | 庫存股份變動 | 每股發行/出售價 (註4) | 已發行股份總數 | | | | 已發行股份（不包括庫存股份）數 | 行股份（不包括庫存股 | | 庫存股份數目 | | | | | | 目 ...

Core Viewpoint - Morgan Stanley Capital International (MSCI) has awarded WuXi AppTec the highest "AAA" ESG rating, making it the first company in the A-share life and health industry to achieve this rating, reflecting its excellence in product safety, human capital development, and corporate governance [1] Group 1: ESG Rating and Performance - WuXi AppTec has maintained an "AA" rating for four consecutive years before achieving the "AAA" rating, indicating its ongoing commitment to ESG initiatives [1] - The MSCI ESG rating system ranges from "AAA" to "CCC," with "AAA" and "AA" representing leading companies in their sectors [1] Group 2: Quality Management and Information Security - WuXi AppTec has established a comprehensive Quality Management System (QMS), with over 80% of its main operational bases certified by international quality standards such as GMP, GLP, GCP, and ISO 9001 [2] - In 2024, the company underwent 802 quality audits from clients and regulatory bodies, achieving 100% compliance [2] - 89% of WuXi AppTec's main operational bases have ISO/IEC 27001 certification for information security management, with no significant incidents of information security breaches reported in 2024 [2] Group 3: Talent Development and Corporate Governance - WuXi AppTec emphasizes talent investment, with 54.71% of its global workforce being female and over 81% holding a bachelor's degree or higher [3] - The company provides an average of 58 hours of training per employee annually and ensures a safe working environment, with 89% of its main operational bases certified under ISO 45001 [3] - WuXi AppTec has integrated ESG into its operations through a robust governance structure, with an ESG committee responsible for setting strategies and monitoring implementation [3] Group 4: Broader ESG Engagement and Recognition - WuXi AppTec has been recognized in multiple ESG ratings, including being listed in the Dow Jones Sustainability Index for four consecutive years and receiving various leadership ratings from CDP and EcoVadis [4] - The company aims to deepen its sustainable practices, having its greenhouse gas reduction targets approved by SBTi and joining the Pharmaceutical Supply Chain Initiative (PSCI) and the United Nations Global Compact (UNGC) [4] - The recognition in ESG ratings underscores WuXi AppTec's credibility on the international stage and its potential for long-term value and sustainable growth [4]

智通财经7月27日电，麦格理将药明康德A股评级上调至跑赢大盘，目标价114元人民币，即上涨28%。 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 | 1). | 購回股份(或其他證券)但沒有註銷 | 302,500 | 0.01 % | RMB | 66.14 | | --- | --- | --- | --- | --- | --- | | | 茲提述本公司於2025年3月17日刊發的公告，於2025年3月26日刊發的 | | | | | | | 通函，及於2025年4月29日刊發的投票結果公告。 | | | | | | | 於2025年6月26日，本公司實施2025年以集中競價交易方式回購本公司 | | | | | | | A股股份方案（"2025年第一次回購"），并回購302,500股A股股份。 | | | | | | | 變動日期 2025年6月26日 | | | | | | | 購回股份(或其他證券)但沒有註銷 | | | | | | 2). | | 303,367 | 0.01 % | RMB | 65.96 | | | 茲提述本公司於2025年3月17日刊發的公告，於2025年3月26日刊發的 | ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 無錫藥明康德新藥開發股份有限公司 呈交日期： 2025年7月25日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 A | | 於香港聯交所上市 | 否 | | | 證券代號 (如上市) | | 說明 | 於上海證券交易所上市 | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | 佔有關事件前的現有已發 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 無錫藥明康德新藥開發股份有限公司 呈交日期： 2025年7月24日 | 1). | 購回股份(或其他證券)但沒有註銷 | 302,500 | 0.01 % | RMB | 66.14 | | --- | --- | --- | --- | --- | --- | | | 茲提述本公司於2025年3月17日刊發的公告，於2025年3月26日刊發的 | | | | | | | 通函，及於2025年4月29日刊發的投票結果公告。 | | | | | | | 於2025年6月26日，本公司實施2025年以集中競價交易方式回購本公司 | | | | | | | A股股份方案（"2025年第一次回購"），并回購302,500股A股股份。 | | | | | | | 變動日期 2025年6月26日 | | | | | | | 購回股份(或其他證券)但沒有註銷 | | | | | | 2). | | 303,367 | 0.01 % | RMB | 65.96 | | | ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 無錫藥明康德新藥開發股份有限公司 呈交日期： 2025年7月24日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 A | | 於香港聯交所上市 | 否 | | | 證券代號 (如上市) | | 說明 | 於上海證券交易所上市 | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | 佔有關事件前的現有已發 ...

Summary of WuXi XDC (2268.HK) Conference Call Company Overview - **Company**: WuXi XDC - **Ticker**: 2268.HK - **Industry**: Contract Research and Development Manufacturing Organization (CRDMO) focused on antibody-drug conjugates (ADCs) and bioconjugates Key Financial Highlights - **1H25 Revenue Growth**: +60% year-over-year (y/y), exceeding Goldman Sachs' estimate of +50% y/y [1] - **Net Profit Growth**: Over +50% y/y, resulting in a net profit margin (NPM) of 27%, compared to 29% in 1H24 and 24% in 2H24 [1] - **Backlog**: As of year-end 2024, backlog reached US$991 million, a +71% y/y increase from US$579 million in 1H24 [5][6] - **New Orders**: New orders for 2H24 are projected to reach US$476 million, with a y/y growth of 47% [5][6] Strategic Insights - **Capacity Expansion**: New capacity in Singapore is expected to come online by the end of 2025, which may impact order intake and pricing strategy [5][9] - **Emerging Modalities**: WuXi XDC is positioned to capture growth in emerging modalities such as RDCs and PDCs, with a focus on differentiating its platform [5] - **Commercial Strategy**: Management anticipates that current commercial projects may start contributing revenue from 2026, with a more significant impact expected from 2027 [5] Market Position and Risks - **China Biotech Licensing**: WuXi XDC is benefiting from a surge in biotech licensing in China, servicing 60% of large-scale deals (>US$1 billion) and leading in IND approvals globally in 2024 [5] - **Legislative Risks**: Potential risks include the impact of the proposed BIOSECURE bill, which could affect federal-funded projects and WuXi's revenue from the U.S. and China [7][8] - **Competitive Landscape**: Increasing competition from global peers and geopolitical uncertainties pose risks to WuXi XDC's market position [7][8] Valuation and Price Target - **12-Month Price Target**: HK$49.30, based on a 12-month forward P/E of 31x [10] - **Market Capitalization**: HK$59.2 billion (approximately US$7.5 billion) [10] Conclusion WuXi XDC is experiencing robust growth driven by strong demand in the ADC and bioconjugate markets, with significant order backlog and new order growth. However, the company faces potential risks from legislative changes and increasing competition. The strategic expansion of capacity and focus on emerging modalities may provide further growth opportunities.

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 無錫藥明康德新藥開發股份有限公司 呈交日期： 2025年7月23日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 A | | 於香港聯交所上市 | 否 | | | 證券代號 (如上市) | | 說明 | 於上海證券交易所上市 | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | 佔有關事件前的現有已發 ...